ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet, ACARIZAX®, has been approved in Canada. The New Drug Submission (NDS) for ACARIZAX® was filed with Health Canada in …